Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

Authors: David A Wiese, Tuddow Thaiwong, Vilma Yuzbasiyan-Gurkan, Matti Kiupel

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Breast cancer is one of the leading causes of cancer deaths. Triple-negative breast cancer (TNBC), an immunophenotype defined by the absence of immunolabeling for estrogen receptor (ER), progesterone receptor (PR) and HER2 protein, has a highly aggressive behavior. A subpopulation of TNBCs exhibit a basal-like morphology with immunohistochemical positivity for cytokeratins 5/6 (CK5/6) and/or epidermal growth factor receptor (EGFR), and have a high incidence of BRCA (breast cancer susceptibility) mutations. Feline mammary adenocarcinomas (FMAs) are highly malignant and share a similar basal-like subtype. The purpose of this study was to classify FMAs according to the current human classification of breast cancer that includes evaluation of ER, PR and HER2 status and expression of basal CK 5/6 and EGFR. Furthermore, we selected triple negative, basal-like FMAs to screen for BRCA mutations similar to those described in human TNBC.

Methods

Twenty four FMAs were classified according to the current human histologic breast cancer classification including immunohistochemistry (IHC) for ER, PR HER2, CK5/6 and EGFR. Genetic alteration and loss of heterozygosity of BRCA1 and BRCA2 genes were analyzed in triple negative, basal-like FMAs.

Results

IHC for ER, PR and HER2 identified 14 of the 24 (58%) FMAs as a triple negative. Furthermore, 11of these 14 (79%) triple negative FMAs had a basal-like subtype. However, no genetic abnormalities were detected in BRCA1 and BRCA2 by direct sequencing and loss of heterozygosity analysis.

Conclusion

FMAs are highly aggressive neoplasms that are commonly triple negative and exhibit a basal-like morphology. This is similar to human TNBC that are also commonly classified as a basal-like subtype. While sequencing of a select number of triple negative, basal-like FMAs and testing for loss of heterozygosity of BRCA1 and BRCA2 did not identify mutations similar to those described in human TNBC, further in-depth evaluation is required to elucidate a potential role of BRCA in the tumorigenesis of triple negative, basal-like FMAs. The strong similarities in clinical behavior, morphology and IHC phenotype suggest that triple negative, basal-like FMAs may be a suitable spontaneous animal model for studying novel therapeutic approaches against human basal-like TNBC.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011, 61: 212-236. 10.3322/caac.20121.CrossRefPubMed
2.
Morris SR, Carey LA: Molecular profiling in breast cancer. Rev Endocr Metab Disord. 2007, 8: 185-198. 10.1007/s11154-007-9035-3.CrossRefPubMed
3.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
4.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed
5.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.CrossRefPubMed
6.
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011, 24: 157-167. 10.1038/modpathol.2010.200.CrossRefPubMed
7.
Haupt B, Ro JY, Schwartz MR: Basal-like breast carcinoma: a phenotypically distinct entity. Arch Pathol Lab Med. 2010, 134: 130-133.PubMed
8.
Anders CK, Carey LA: Biology, metastatic patterns and treatment of patients withtriple negative breast cancers. Clin Breast Cancer. 2009, 9 (Suppl 2): S73-S81.CrossRefPubMedPubMedCentral
9.
Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast. 2010, 19: 312-321. 10.1016/j.breast.2010.03.026.CrossRefPubMed
10.
Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, Christiaens MR, Paridaens R, Wildiers H: Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast. 2013, Feb 15 [Epub ahead of print]
11.
Ismail-Khan R, Bui MM: A review of triple-negative breast cancer. Cancer Control. 2010, 17: 173-176.PubMed
12.
Hayes H, Milne K, Mandell C: Epidemiological features of feline mammary carcinoma. Vet Rec. 1981, 30: 476-479.CrossRef
13.
Misdorp W, Else RW, Hellme’n E, Lipscomb TP: Histological classification of mammary tumors of the Dog and Cat. Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, vol. VII. 2nd series. Washington, DC. 1999, 1-59.
14.
Dias Pereira P, Carvalheira J, Gärtner F: Cell proliferation in feline normal hyperplastic and neoplastic mammary tissue--an immunohistochemical study. Vet J. 2004, 168: 180-185. 10.1016/j.tvjl.2003.10.018.CrossRefPubMed
15.
Hahn K, Bravo L, Avenell J: Feline breast carcinoma as a pathologic andtherapeutic model for human breast cancer. In Vivo. 1994, 8: 825-828.PubMed
16.
Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M: Feline mammary tumours in comparative oncology. J Dairy Res. 2005, 72 (Spec No): 98-106.CrossRefPubMed
17.
Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, Uzzau S, Antuofermo E: Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer. 2010, 10: 156-10.1186/1471-2407-10-156.CrossRefPubMedPubMedCentral
18.
Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V: An Immunohistochemical study of HER2 expression in feline mammary tumours. J Comp Pathol. 2011, 144: 170-179. 10.1016/j.jcpa.2010.08.010.CrossRefPubMed
19.
Hamilton JM, Else RW, Forshaw P: Oestrogen receptors in feline mammary carcinoma. Vet Rec. 1976, 99: 477-479. 10.1136/vr.99.24.477.CrossRefPubMed
20.
Rutteman GR, Blankenstein MA, Minke J, Misdorp W: Steroid receptors in mammary tumours of the cat. Acta Endocrinol (Copenh). 1991, 125 (Suppl 1): 32-37.
21.
Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A: Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci. 2005, 79: 225-232. 10.1016/j.rvsc.2005.02.002.CrossRefPubMed
22.
Mulas JM D l, van Niel M, Millán Y, Blankenstein MA, van Mil F, Misdorp W: Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol. 2000, 18: 111-125. 10.1016/S0739-7240(99)00067-3.CrossRefPubMed
23.
Mulas JM D l, Van Niel M, Millán Y, Ordás J, Blankenstein MA, Van Mil F, Misdorp W: Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci. 2002, 72: 153-161. 10.1053/rvsc.2001.0542.CrossRef
24.
De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF: Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65: 907-912.PubMed
25.
Ordas J, Millan Y, Dios R, Reymundo C, De las Mulas JM: Proto-oncogene HER2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer. 2007, 7: 179-184. 10.1186/1471-2407-7-179.CrossRefPubMedPubMedCentral
26.
Hughes K, Dobson JM: Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012, 194: 19-26. 10.1016/j.tvjl.2012.05.008.CrossRefPubMed
27.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Sciencen. 1994, 266: 66-71. 10.1126/science.7545954.CrossRef
28.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed
29.
Miller BJ, Wang D, Krahe R, Wright FA: Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet. 2003, 73: 748-767. 10.1086/378522.CrossRefPubMedPubMedCentral
30.
Osorio A, de la Hoya M, Rodríguez-López R, Martínez-Ramírez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldés T, Benítez J: Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 2002, 99: 305-309. 10.1002/ijc.10337.CrossRefPubMed
31.
Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003, 95: 1482-1485. 10.1093/jnci/djg050.CrossRefPubMed
32.
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.CrossRefPubMed
33.
Veer LJ V ’t, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRef
34.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histologic grade in breast cancer: experience from a large study with long term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
35.
Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002, 39: 529-535. 10.1354/vp.39-5-529.CrossRefPubMed
36.
Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A: BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007, 16: 280-292. 10.1016/j.breast.2006.12.003.CrossRefPubMed
37.
Oetting WS, Lee HK, Flanders DJ, Wiesner GL, Sellers TA, King RA: Linkage analysis with multiplexed short tandem repeat polymorphisms using infrared fluorescence and M13 tailed primers. Genomics. 1995, 30: 450-458. 10.1006/geno.1995.1264.CrossRefPubMed
38.
Powell CA, Klares S, O’Connor G, Brody JS: Loss of heterozygosity in epithelial cells obtained by bronchial brushings: clinical utility in lung cancer. Clin Cancer Res. 1999, 5: 2025-2034.PubMed
39.
Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol. 1998, 119: 263-275. 10.1016/S0021-9975(98)80049-2.CrossRefPubMed
40.
Morgan MP, Cooke MM, McCarthy GM: Microcalcifications associated with breast cancer: an epiphenoenon or biologically significant feature of selected tumors?. J Mammary Gland Biol Neoplasia. 2005, 10: 181-187. 10.1007/s10911-005-5400-6.CrossRefPubMed
41.
Tornos C, Silva E, el Naggar A, Pritzker KP: Calcium oxalate crystals in breast biopsies. The missing microcalcifications. Am J Surg Pathol. 1990, 14: 961-968. 10.1097/00000478-199010000-00010.CrossRefPubMed
42.
Zafrani B, Aubriot MH, Mouret E, De Crémoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelénat H, Sastre-Garau X: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000, 37: 536-545. 10.1046/j.1365-2559.2000.01006.x.CrossRefPubMed
43.
Lal P, Tan LK, Chen B: Correlation of HER2 status with estrogen and Progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005, 123: 541-546. 10.1309/YMJ3A83TB39MRUT9.CrossRefPubMed
44.
Winston J, Craft DM, Scase TJ, Bergman PJ: Immunohistochemical detection of HER2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol. 2005, 3: 8-15. 10.1111/j.1476-5810.2005.00063.x.CrossRefPubMed
45.
Millanta F, Calandrella M, Citi S, Della Santa D, Poli A: Overexpression of HER2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol. 2005, 42: 30-34. 10.1354/vp.42-1-30.CrossRefPubMed
46.
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian Breast & Colorectal Cancer Study Group: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER2 protein expression in breast cancer. Clin Cancer Res. 2001, 7: 1669-1675.PubMed
47.
Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S: Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009, 22: 1457-1467. 10.1038/modpathol.2009.117.CrossRefPubMed
48.
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J ClinOncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.CrossRef
49.
Ibarra JA, Rogers LW, Kyshtoobayeva A, Bloom K: Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol. 2010, 133: 747-755. 10.1309/AJCPPIUHS4GVAR0I.CrossRefPubMed
50.
Arber DA: Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunhohistochem Mol Morphol. 2002, 10: 183-186. 10.1097/00022744-200206000-00015.
51.
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009, 15: 2302-2310. 10.1158/1078-0432.CCR-08-2132.CrossRefPubMed
52.
Diaz LK, Cryns VL, Symmans WF, Sneige N: Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007, 14: 419-430. 10.1097/PAP.0b013e3181594733.CrossRefPubMed
Metadata
Title
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Authors
David A Wiese
Tuddow Thaiwong
Vilma Yuzbasiyan-Gurkan
Matti Kiupel
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-403

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Metabolic system alterations in pancreatic cancer patient serum: potential for early detection

Research article

OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2

Research article

Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study

Research article

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia

Research article

Inverse expression of hyaluronidase 2 and hyaluronan synthases 1–3 is associated with reduced hyaluronan content in malignant cutaneous melanoma

Research article

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits